Stocks of a vital cancer drug are running low in the US, which could affect children with leukaemia within weeks.
The US Food and Drug Administration says a number of drug manufacturers are flagging up shortages in methotrexate – which slows the growth of white blood cells in acute lymphoblastic leukaemia, a cancer that typically affects young children.
Manufacturing
delays and unexpectedly high levels of demand are blamed for the
shortfall, together with the voluntary closure of Ben Venue
Laboratories, one of the nation's largest suppliers of the drug.
Oncologists
are concerned supplies could run out in some areas within weeks.
Reports suggest that the FDA is seeking a foreign supplier to provide
emergency imports until domestic ones can meet demand.
Legislation designed to give an early warning of drug shortages was passed to a government committee last summer.
Nerve cells like these could be controlled by quantum dots (Image: CNRI/Science Photo Library)
In an unlikely marriage of quantum physics and
neuroscience, tiny particles called quantum dots have been used to
control brain cells for the first time.
Having
such control over the brain could one day provide a non-invasive
treatment for conditions such as Alzheimer's disease, depression and
epilepsy. In the nearer term, quantum dots could be used to treat
blindness by reactivating damaged retinal cells.
"Many brain disorders are caused by imbalanced neural activity," says Lih Lin
at the University of Washington, Seattle. "Manipulation of specific
neurons could permit the restoration of normal activity levels."
Methods
to stimulate the brain artificially already exist, though each has its
drawbacks. Deep brain stimulation is used in Parkinson's disease to
trigger brain cell activity and prevent the abnormal signalling that
causes debilitating tremors, but placing the electrodes required is
highly invasive. Transcranial magnetic stimulation can stimulate brain
cells from
outside
the head, but is not highly targeted and so affects large areas of the
brain at once. Researchers in optogenetics can control genetically
modified brain cells using light but because of these modifications,
the technique is not yet deemed safe to use in humans.
Lin's
team has now come up with an alternative using quantum dots –
light-sensitive, semiconducting particles just a few nanometres in
diameter.
First,
they cultivated prostate cancer cells on a film covered with quantum
dots. The cell membranes of the cancer cells were positioned next to
the dots. The team then shone light onto the nanoparticles.
Energy from the light excites electrons within the quantum dot which causes the surrounding area to become negatively charged (see diagram).
This caused some of the cancer cells' ion channels, which are mediated
by a voltage, to open, allowing ions to rush in or out of the cells.
In
nerve cells, opening ion channels is a crucial step in generating
action potentials – the signals by which the cells communicate in the
brain. If the voltage change is large enough, an action potential is
generated.
When
Lin's team repeated their experiment with nerve cells, they found that
stimulating the quantum dots caused ion channels to open and the nerve
cell to fire.
In
humans, quantum dots would need to be delivered to brain tissue. Lin
claims this shouldn't be a problem. "A significant advantage is that
their surface can be modified with various molecules," she says. These
molecules could be attached to the quantum dots in order to target specific brain cells and could be administered intravenously.
A
key hurdle would be delivering the light source to the brain. For this
reason, Lin reckons the first use for the technique would be in
reactivating damaged cells in the retina, which naturally absorb light.
Co-author Fred Reike, who specialises in retinal disease, says that
quantum dots have great potential in this area because they directly
affect ion channels, which play a key part in the signalling pathways
of vision.
"Quantum dots have a great future for biomedical applications," agrees Kevin Critchley at the University of Leeds, UK, but adds that there are limitations such as potential toxicity issues.
"Based
on what we have observed, we are optimistic about the potential of this
technology in helping us [answer] biological questions, and eventually
diagnose and treat human diseases," Lin says.
The "cuddle chemical" oxytocin bonds mothers to their babies and
sniffing it makes adults nicer – but can also foster gloating and racism
FEW
chemicals have as glowing a reputation as oxytocin. Billed as the "love
hormone" or the "cuddle chemical", it has been linked to almost every
positive aspect of the human psyche. One whiff of it can make a person
more trusting, empathetic, generous and cooperative. Such is its
popular appeal that you can even buy it as a spray from dubious
internet dealers.
It
is time to revise this rose-tinted view. A new wave of studies is
showing that oxytocin is neither the cause of our better angels nor a
panacea for the world's social ills. In fact, its effects vary greatly
depending on the person and the circumstances, and it can tweak our
social interactions for worse as well as for better. The "love
hormone", it turns out, has a dark side, one that is only just starting
to come to light. "It isn't the wonder drug that makes everyone happy
and social," says Markus Heinrichs at the University of Freiburg,
Germany, who pioneered work on oxytocin.
We
first became aware of the hormone's social influence through animal
studies. It helps to cement the bonds between prairie voles, which mate
for life, and triggers the motherly behaviour that sheep show towards
their newborn lambs. It is also released in humans during childbirth,
strengthening the attachment between mother and baby.
Its
wider role in human behaviour only emerged in 2005 when, in a
groundbreaking experiment, Heinrichs and colleagues asked volunteers to
play a game in which they could invest money with an anonymous trustee,
who was not guaranteed to be honest. The team found that participants
who had sniffed oxytocin via a nasal spray beforehand invested more
money than those given a placebo (Nature, vol 435, p 673).
The
study kick-started research into the effects of oxytocin on human
behaviour. "For eight years, it was quite a lonesome field," Heinrichs
recalls. "Now, everyone is interested." Many of the follow-up studies
came from the same mould as the original experiment, involving groups
of volunteers being given either oxytocin or a placebo and then
carrying out a task to test their social skills. Such studies have
shown that after a sniff of the hormone, people donate more money to
charity, become better at reading emotions on other people's faces,
communicate more constructively during arguments, and perceive others
to be more trustworthy, attractive and approachable. Together, the
results fuelled the view that oxytocin universally enhances the
positive aspects of our social nature.
Then,
a couple of years ago, contrasting findings began to emerge. Simone
Shamay-Tsoory at the University of Haifa, Israel, showed that as well
as promoting trust and generosity, oxytocin can heighten feelings of
envy and schadenfreude (Journal of Biological Psychiatry, vol
66, p 864). When volunteers played a gambling game, those who inhaled
the hormone gloated more when they beat other players. They also felt
sharper stabs of jealousy when the tables were turned. Clearly,
oxytocin can produce antisocial as well as social behaviour.
A
new wave of studies is showing that oxytocin is neither the cause of
our better angels nor a panacea for the world's social ills (Image: Phil Ball/Rex Features)
That's
not all. The hormone also has sharply contrasting effects depending on
a person's disposition. Jennifer Bartz from the Mount Sinai School of
Medicine, New York, found that it improves people's ability to read
emotions, but only if they are not very socially adept to begin with (Psychological Science, vol 21, p 1426).
Her team also showed that oxytocin actually reduces trust and
cooperation in people who are particularly anxious or sensitive to
rejection (Social Cognitive and Affective Neuroscience, vol 6, p 556).
It can even alter our memories in different ways. It gives people
fonder recollections of their mothers, but only if they are secure in
their personal relationships. If they are socially anxious, oxytocin
makes them remember their mums as being less caring and more distant (Proceedings of the National Academy of Sciences, vol 107, p 21371).
The
effects of oxytocin can also depend on a person's culture. Although we
have yet to fully unravel the complex biochemical pathways by which
this hormone shapes behaviour, we do know that it starts off by docking
onto a protein found throughout the nervous and reproductive systems,
one encoded by the OXTR gene. A change in one of the gene's DNA
letters, from A to G, makes people more socially sensitive. G-carriers
tend to be more empathetic and less lonely. They are also more likely
to turn to their friends in times of trouble, but only if they live in
a culture where it is customary to seek companionship when distressed.
Heejung Kim of the University of California, Santa Barbara, found that
in South Korea - where it is often a faux pas to burden friends with
your problems - G-carriers are no more likely, and may in fact be
slightly less likely, to seek solace from their social circles than
A-carriers (Proceedings of the National Academy of Sciences, vol 107, p 15717). So a single trait, social sensitivity, plays out in radically different ways against the backdrops of different cultures.
Another discovery is that oxytocin's effects vary
depending on who we interact with. Carolyn DeClerck of the University
of Antwerp, Belgium, found that people under the hormone's influence
become more cooperative only if they have some information about their
partner. When paired with anonymous strangers, they become less
cooperative. Meanwhile, Carsten de Dreu at the University of Amsterdam
in the Netherlands discovered that oxytocin-sniffers show more trust
and cooperation towards their compatriots, but not people of other
nationalities (Science, vol 328, p 1408).
They also showed favouritism: Dutch men became quicker to associate
positive words with Dutch names than with German or Arabic ones, for
example. De Dreu says that oxytocin promotes a "tend and defend"
response, one that drives people to care for those in their social
circles and protect them from outside dangers. "It's what we call the
mama-bear effect," he says. So, rather than promoting blanket goodwill,
oxytocin strengthens biases.
There
were signs of these subtleties from the start. Bartz has recently shown
that in almost half the existing studies, oxytocin held sway only over
certain individuals or in particular circumstances (Trends in Cognitive Sciences, vol 15, p 301).
Where once researchers ignored such findings, now a more nuanced
understanding of oxytocin's effects is propelling investigations down
new lines.
To
Bartz, the key to understanding what the hormone does lies in
pinpointing its core function rather than in cataloguing its seemingly
endless effects. There are several hypotheses, which are not
necessarily mutually exclusive. Oxytocin could help to reduce anxiety
and fear. Or it could simply motivate people to seek out social
connections, which would account for a rise in trust and cooperation,
but also explain why oxytocin-sniffers gravitate towards others
resembling themselves, and why people who fear social rejection are not
necessarily better off with more of the hormone.
For
her part, Bartz favours the social salience hypothesis. The idea here
is that oxytocin acts as a chemical spotlight that shines on social
cues - a shift in posture, a flicker of the eyes, a dip in the voice -
making people more attuned to their social environment. This would
explain why it makes us more likely to look others in the eye and
improves our ability to identify emotions. For people with autism who
are less able to pick up on social cues, oxytocin could bring those
subtle signs into sharp focus (see "Treat with care").
But it could make things worse for people who are overly sensitive and
prone to interpreting social cues in the worst light. "People may
become more empathic or protective, but they may also become more
vigilant or competitive," says De Dreu. "It depends on who they are and
the other people that they're dealing with."
Perhaps
we should not be surprised that the oxytocin story has got more
complicated. The hormone is found in everything from octopuses to
sheep, and its evolutionary roots stretch back half a billion years.
"It's a very simple and ancient molecule that has been co-opted for
many different functions, from lactation to social behaviour," says Sue
Carter at the University of Illinois, Chicago, who did many of the
early studies in animals. "It affects primitive parts of the brain like
the amygdala, so it's going to have many effects on just about
everything." Bartz agrees. "Oxytocin probably does some very basic
things, but once you add our higher-order thinking and complex
behaviours and social situations, these basic processes could manifest
in different ways depending on individual differences and context."
Treat with care
With
around 40 clinical trials under way using oxytocin to treat conditions
such as autism and schizophrenia, there is a lot of optimism that the
hormone could help people by boosting trust and reducing social
anxiety. However, there is also a growing realisation that under
certain circumstances oxytocin can make people more antisocial (see
main story). Understanding these subtle effects could mean the
difference between helping someone and making things worse.
"From
the early data, it's very clear that oxytocin alone will do nothing,"
says Markus Heinrichs at the University of Freiburg, Germany. "If you
sit at home with a social phobia and someone prescribes a nasal
oxytocin spray, I bet that the only effect you'd get would be a
dripping nose." The trick is to work out when and in whom oxytocin
would be expected to improve social behaviour, undermine it, or do
nothing. For example, people might respond differently depending on how
much of the hormone naturally courses through their blood, their
emotional state at the time of inhalation, or which version of a gene
called OXTR they have. Combining treatment with counselling
should help get the best results, provided people identify with their
therapist and so are likely to experience the positive side of
oxytocin's effects.
Researchers
are addressing these issues, but meanwhile oxytocin sprays are readily
available online. "We know people are buying it off the internet and
trying to use it to treat children with autism," says Sue Carter at the
University of Illinois, Chicago. In most cases, the amount of hormone
in the sprays is so low that they cannot be effective. Still, Carter
points out that no one knows the long-term consequences of inhaling
oxytocin, or what happens when you give it to young children. "This is
very worrying," she says.
Do British people know enough about the financial interests of those writing health articles? Time to toughen editorial codes
LAST
year, the BBC News website published an article that questioned if
psychological therapies were enough to tackle the rise of depression in
the UK. "Is it time," asked the author, "to question our seeming
obsession with talking treatments? I want to stand up for the very
important role medication can play in the treatment of mental illness."
What
stood out for me was not just the pro-pill stance, but an endnote that
its author, Richard Gray, a professor in nursing research at the
University of East Anglia, Norwich, had "given lectures on behalf of a
number of pharmaceutical companies". It did not state he had been paid
for them, or that he had received fees and honoraria from
antidepressant manufacturers, including AstraZeneca and Eli Lilly, for
consultancy work.
This
kind of omission happens all the time, so why single out this case?
Primarily because the site is run by the BBC, a global media
corporation. And the thousands reading the article could not judge its
impartiality because they did not know about the payments.
After trying to get a comment for some time, the BBC agreed to amend the endnote. But at medical journals such as The Lancet
failure to disclose payments would have breached editorial codes. In
the UK, we rely on codes, in the US, media outlets are legally obliged
to declare potential vested interests.
Sophie
Corlett of Mind, a UK mental health charity, thinks we should take this
seriously. "People experiencing mental health problems look to
professionals... for many, this includes information that filters
through the media. The responsibility to inform readers of issues which
may affect the impartiality of a published piece lies with... news
outlets and contributing authors. Mind has long campaigned for medical
information to be conveyed in an open and balanced manner... we
encourage... disclosure of interests."
This
is happening at a time when concern is mounting over industry influence
on psychiatric research and practice, and on public opinion. Trials of
antidepressants are mostly funded, and often analysed and directed, by
pharmaceutical companies. Some 60 per cent of the task force behind DSM-IV
(the psychiatrists' diagnostics handbook) received money from pharma,
as have most research centres and many heads of psychiatry schools. Of
the 29 experts writing DSM-5, 21 received honoraria, consultancy fees or funding from pharma.
The
BBC defends its coverage: "It's common for the BBC to speak to people
with expertise in a particular subject. We do so under clear editorial
guidelines that contributors associated with a particular viewpoint or
with a commercial interest in a subject should be clearly signposted...
Nothing has been put to us which suggests that there has been any
conflict of interest."
So
the BBC aims to ensure articles are signposted. In this case one
slipped through the net and was duly amended. But it must be more alert
to contentious topics and conflicts of interest. Perhaps its code needs
tightening - or we should consider a law.
James Davies is a senior lecturer in social anthropology and psychotherapy at the University of Roehampton, London
Maltreatment of children may stunt growth of the
hippocampus, a brain region vital for memory. That's the conclusion of
a study of 193 outwardly healthy adults aged 18 to 25 from the Boston
area.
The
stunted hippocampi could help explain how childhood stress raises the
risk of psychiatric disorders in adulthood, ranging from depression,
schizophrenia and post-traumatic stress disorder to personality
disorders, drug addiction and even suicide.
Martin Teicher
of McLean Hospital in Belmont, Massachusetts, and colleagues used
standard questionnaires to reveal which volunteers had suffered abuse
as children, and found size differences in regions of the hippocampus
through detailed MRI brain scans.
Big
differences were seen in people who said that as children they had
experienced verbal, physical or sexual abuse, physical or emotional
neglect, bereavement, parental separation or parental discord. Three
sub-regions of the hippocampus were between 5.8 and 6.5 per cent
smaller in such volunteers, compared with those who reported no
maltreatment.
Stress strike
The
three sub-regions – the dentate gyrus, the cornu ammonis and the
subiculum – are all known to be vulnerable to the effects of stress
hormones, which probably interfere with the formation of cells and new
tissue as the immature brain develops.
"These
findings support the hypothesis that exposure to early stress in
humans, as in other animals, affects hippocampal development,"
concludes Teicher's team. They say that the study is the largest and
most detailed yet to examine the phenomenon in people, and the results
echo those seen in the hippocampi of rats and monkeys subjected to
stress as infants.
Child abuse or poverty can also alter which genes are active in the developing brain through a process called epigenesis. These changes can lead to diseases such as schizophrenia and bipolar disorder.
"Childhood maltreatment is like a surgical strike on the brain," says Carmine Pariante,
who studies the effects of stress on child development at the Institute
of Psychiatry, Kings College London. "This explains why these
individuals are at risk of developing a host of stress-related
disorders later in life – because they have an impaired ability to cope
with stress."
"Findings like this indicate that maltreatment can leave damage hidden deep inside the body that persists for many years," says Terrie Moffitt
of Duke University in Durham, North Carolina. "Once we appreciate that
child maltreatment brings hidden damage that can resurface years later
as memory problems, preventing child abuse seems like a very good deal."
Journal reference: Proceedings of the National Academy of Sciences, DOI: 10.1073/pnas.1115396109
A flowering Tibetan shrub that tricks cells into
thinking they are starving could become a weapon against multiple
sclerosis and even old age.
The roots of the blue evergreen hydrangea (Dichroa febrifuga) have been used for centuries in traditional Chinese medicine to treat malaria. Now Tracy Keller
and colleagues at the Harvard School of Dental Medicine in Boston have
found that halofuginone – a chemical based on the roots' active
ingredient – blocks immune reactions that can cause disease.
Cells
stop the synthesis of non-vital proteins when amino acids are in short
supply. Keller's team discovered that halofuginone mimics such a
shortage by blocking an enzyme that feeds one amino acid to the
protein-making machinery.
Keller
found that the drug triggers a chemical cascade that responds to amino
acid scarcity, called AAR. This inhibits the growth of malaria
parasites, stops blood cells from making proteins that cause
inflammation, and stops the development of specific white blood cells
that trigger conditions such as inflammatory bowel disease and multiple
sclerosis.
This
could make the drug effective against autoimmune disease. But as
halofuginone mimics nutrient deprivation, there is another possible
use. Animals that receive only just adequate nutrition are known to live longer,
partly because diseases which involve inflammation are prevented. That,
says Keller, means halofuginone might possibly work as an anti-ageing
drug.
Journal reference: Nature Chemical Biology, DOI: 10.1038/nchembio.790
You've got a lot of nerve (Image: Science Picture Co/Science Faction/Corbis Left:SPL/Corbis)
THE once paralysed limb began to twitch just minutes
after the operation. It was an early sign that the rat was on a fast
track to recovery that would see it up and running within weeks.
The
rodent is one of more than 200 to have undergone a new surgical
procedure for nerve repair that provides faster - and better - results
in animals than existing techniques. The crucial question is: can it
work as well in humans with the sorts of injuries that the real world
inflicts upon us?
"In animal models, the results are better than any current techniques used for nerve repair," says Wesley Thayer of Vanderbilt University in Nashville, Tennessee, a member of the team behind the new procedure.
So far, Thayer and team leader George Bittner
of the University of Texas at Austin have used the new technique to
treat rats after severing their sciatic nerve, which mediates leg
movement and feeling. With plans afoot to begin clinical trials and
work also under way to see if the procedure can heal spinal cord
injuries in rats, nerve specialists are cautiously optimistic that
Bittner and Thayer are on to something.
When
a nerve is severed through injury, surgeons must suture the two stumps
together as quickly as possible. Yet even under controlled lab
conditions, Bittner's tests in rats suggest that these conventional
sutures restore little more than 30 per cent of previous mobility, even
three months after surgery. His new technique helps to restore twice
that, in as little as two weeks. The secret, he says, is to prevent the
body lending a helping hand.
Put
bluntly, the body botches nerve repair. It forms seals over the two
severed stumps of a broken nerve within an hour, says Bittner, but it
doesn't reconnect them first. Even if surgeons then suture the two
ends, the seals will prevent nerve signals from passing easily across
the join (see "Bound together").
Bittner
realised that we need a system that blocks the body's repair process.
The way to do that, he discovered, is to immediately flush the injury
site with a calcium-free salty solution that also contains methylene
blue, a chemical that blocks oxidation reactions. Calcium and oxidation
drive the formation of tiny spheres called vesicles, which in turn seal
the nerve stumps.
The
two still-unsealed stumps can then be glued together using polyethylene
glycol, or PEG, which Bittner says allows the outer insulating layers
of the nerve to join up more efficiently than they would through
suturing.
Only
when the nerve has been glued together does Bittner restart the body's
natural local repair mechanism - by injecting a calcium-rich salty
solution. Vesicles quickly consolidate the join (Journal of Neuroscience Research, DOI: 10.1002/jnr.23022 and 10.1002/jnr.23023).
All
the substances for the procedure are already in medical use. "We are
planning a small clinical trial once we have more safety data," says
Thayer.
Work
is also under way to see if the technique could help heal the spinal
cord as well as the nerves that branch from it. Bittner says he's
already shown that the new procedure works on spinal cords "in a dish",
and evaluations in animals have been done too, but he is keeping these
results under wraps until the work is published in a peer-reviewed
journal.
Other
nerve specialists are fascinated by the results, but all warn that the
outcome might not be as impressive in injured humans because real-world
wounds are often much more complex than those produced in the lab rats.
"Clinical injuries are normally messy, not carefully controlled
microlesions," says John Priestley of Queen Mary, University of London.
Giorgio Terenghi
at the University of Manchester, UK, says that the technique won't work
in people with injuries that are more than a few days old. Not only
will the nerve stumps have sealed, but the chunk of nerve cut adrift
from the rest of the nervous system begins to decay. Bittner and Thayer
say they are working on ways to improve the survival time of the
isolated section.
The
caution greeting the new work is understandable, given that researchers
are keen to avoid raising hopes prematurely. But it was also mixed with
optimism. "As a beginning it's very encouraging," says Terenghi.
"It
would be a major breakthrough if the severed pieces of a nerve could be
just glued together - although most research indicates that this is not
possible," says Priestley. "The two new papers describe something truly
startling and exciting."
What a quick turnaround: a drug used to treat cancer
can reverse Alzheimer's disease in mice – and it takes just 72 hours to
work its magic. It remains to be seen if the drug has the same effect
in people with Alzheimer's, though.
Alzheimer's disease
is associated with deposits of beta-amyloid peptides in the brain. The
build-up is thought to underlie the abnormal brain activity that leads
to memory problems, and also kick-starts a chemical cascade that
ultimately leads to the death of neurons.
Paige Cramer
at Case Western Reserve University School of Medicine in Cleveland,
Ohio, reckoned it might be possible to prevent that build-up using
bexarotene, an anti-cancer drug. She reasoned that a healthy brain can
clear beta-amyloid deposits through a process facilitated by a
substance called apolipoprotein E (ApoE). ApoE is activated in part by
a receptor called RXR – and bexarotene enhances the action of RXR.
When
mice with Alzheimer's-like brain damage were given bexarotene orally,
they were able to clear more than half of the beta-amyloid peptides
from the brain within 72 hours. They also showed a rapid reversal of
cognitive and social deficits.
Cramer
says she hopes to begin phase 1 clinical trials in the next few months.
"We believe that because bexarotene is approved [for use in humans], we
will be able to transition much more quickly from basic research to the
clinic," she says.
Caution needed
Other
researchers caution that the study, while encouraging, does not mean
that the drug will work so well in people with Alzheimer's. Many drugs
that have shown promising results in mice fail to have similar effects in humans.
"The drug development world is littered with drugs that seemed to work on transgenic mice, but didn't work on people," says Derek Hill
at University College London. "A programme of clinical trials is needed
to assess whether these potentially promising results translate into an
effect on the human disease."
David Allsop,
a neuroscientist at the University of Lancaster, UK, agrees. "It looks
promising in the mouse model, but in recent years these types of
experiments in mice have not translated well into humans, and so it is
too early to get excited about the prospect of an effective therapy for
Alzheimer's disease," he says